New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
08:33 EDTIDRAIdera Pharmaceuticals initiates dosing in Phase 1 trial of IMO-8400
Idera Pharmaceuticals announced the initiation of dosing in a Phase 1 trial of IMO-8400. IMO-8400 is an antagonist of Toll-like receptors, or TLRs, 7, 8 and 9, and is the second clinical candidate in Idera's autoimmune disease program. Idera expects to develop IMO-8400 for the treatment of lupus as an initial indication. Idera also announced the presentation of preclinical data on IMO-8400 at the American College of Rheumatology that support its potential to treat autoimmune diseases through inhibition of Th1, Th17, and inflammasome activation
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
08:19 EDTIDRAIdera Pharmaceuticals advanced IMO-9200 into Phase 1 clinical development
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use